~~<i id='012B91A7EE'><strike id='012B91A7EE'><tt id='012B91A7EE'><pre id='012B91A7EE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：explore 2025-08-19 18:00:43 - browse：2841

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Data integrity in scientific journals requires "effort" by publishers, institutions

entertainment

hotspot

explore

hotspot

explore

AdobeItmakessenseintheoryforhospitalsandstartupstostrikedeals.Notonlywoulddoctorsgetfirstdibsonnewhe

WSS

Vertigo drug brings hope for rare neuron disorder, Niemann

Juul spent big to court Black leaders to promote its e

Quicker fix for pulse oximeters urged during FDA public meeting

Woodcock on FDA’s accelerated approval and her next chapter

Juul spent big to court Black leaders to promote its e

Second House panel advances two

focus

entertainment

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

ARCH Venture Partners is raising $3 billion for a life sciences fund

Wildfire smoke exposes gaps in outdoor worker protections

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Apple is now the first public company to be valued at $3 trillion

What we need to know about Arena Bioworks

Alkermes shareholders re

FDA drug safety: Singulair case shows systemic surveillance flaws

Hepatitis C has a cure — but many Americans still lack access to it

With measles on the rise, a personal story of a devastating disease

hotspot

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Congressmen charge Covid hearing ‘could have been an email’

What we need to know about Arena Bioworks

Covid misinformation case heads to Supreme Court

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

explore

explore

hotspot

explore